The Global Fund support for Tuberculosis control STOP TB Symposium 3 December 2009, Cancun Prof. Rifat Atun and Dr Mohamed Aziz

1.Global Fund support for the 3 diseases 2.Global Fund support for Tuberculosis 3.Round 9 for TB 4.Results achieved 5.The way forward

Countries with Global Fund Grants BG/281108/7

Regional Distribution Rounds 1-8, (July 2009) 100% = US$ 15.9 billion Percentages of total funds approved by the Board, including Phase 2 & RCC Global Fund Grant Resources by Region OP/140709/2

Country Classification: by Income level Rounds 1-8, (July 2009) 100% =US$ 15.9 billion Percentages of total funds approved by the Board, including Phase 2 & RCC Global Fund Grant Resources by Income Level OP/140709/1

How are Grant Funds Used? Resources by Expenditure Component OP/140108/6

1.Global Fund support for the 3 diseases 2.Global Fund support for Tuberculosis 3.Round 9 for TB 4.Results achieved 5.The way forward

Rounds 5-9: success rates by disease area

TB success rates (excluding HSS parts) Rounds Eligible proposals Recommended proposals Success rate Round 9 & NSAs % Round % Round % Round % Round % Total Phase 1 funding approved: US$2.1 billion

Disease Components Distribution Rounds 1-8, (July 2009) Global Fund Resources by Disease Component 100% = US$ 15.9 billion Percentages of total funds approved by the Board, including Phase 2 & RCC OP/140709/3

Global Fund Contribution to International Financing for Tuberculosis, 2008 Global Fund provided 57% of all international funding in 2008 Source: WHO Stop TB data, 2008 SE/260309/4

Tuberculosis Coverage After 8 Rounds of proposals 110 countries 184 components US$ 1.2 billion (2 years) US$ 3.1 billion (5 years) BG/281108/9

1.Global Fund support for the 3 diseases 2.Global Fund support for Tuberculosis 3.Round 9 for TB 4.Results achieved 5.The way forward

Round 9 and NSA Funding Recommendations Phase 1 upper-ceiling amounts recommended by the TRP for Round 9 and the First Learning Wave of National Strategy Applications (NSA) and AMFm: Round 9US $ 2.2 billion NSA FLWUS $ 434 million Total Round 9 and NSA FLW recommended for funding: US $ 2.6 billion (Phase 1) and US $ 7.2 (Lifetime budget) (Board decision: 20 th Board Meeting)

Round 9 and NSA Funding Recommendations Round 9 overall success rate: 53% (85 of 159) (includes HSS s4B/5B) NSA overall success rate: 71% (5 of 7) 2 new single country beneficiaries recommended: Mexico and Turkmenistan

Round 9 - Number of proposals recommended and success rates Success rate41% 59% 55% 50% Round 9 success rates (excluding HSS s4B/5B)

Round 9: Disease parts by TRP recommendation category and by disease HIVTuberculosisMalariaOverall Category 1 Category 2 Category 2B Category 3 Category 4 41% 59%55% 50% Recommended for funding

Round 9 TB funding recommendations: by region

NSA - Number of proposals recommended and success rates Success rate 33% 100% 100% 71%

Round 9: HSS cross-cutting requests Round 9 Success rate 52% 43% 50% 50% Round 8 Success rate 56% 50% 50% 53%

1.Global Fund support for the 3 diseases 2.Global Fund support for Tuberculosis 3.Round 9 for TB 4.Results achieved 5.The way forward

TB financing and cumulative new sputum positive cases detected and treated, by year

How Do Results Scale-up? June 2009 GP/110608/9

Average grant performance (results vs. grant targets) over time Performance: results vs. agreed-upon, time- bound targets

Achievement To date, The GF approved treatment of MDR cases Yet less than half of the cases are treated through the GLC mechanism With Round 9 grant life the total MDR supported with GF funding will reach patients

1.Global Fund support for the 3 diseases 2.Global Fund support for Tuberculosis 3.Round 9 for TB 4.Results achieved 5.The way forward

1.Universal access to high quality TB control measures. 2. Better targeted TB proposals which will increase success rate 3. Increased emphasis on TB/HIV collaborative activities Round 9 – not all TB proposals did include HIV activities and vice versa Better communication from The Global Fund and Technical Organisations

4.Increased demonstration of cost-effectiveness of tuberculosis prevalence surveys in proposals as recommended by TRP in Round 9 5.Repackaging TB messages to make it more positive and increase the focus on achievements and success stories. 6.Urgent need to scale up MDR treatment. 7.Inclusion of infection control measures. 8. Better demonstration of HSS support in TB proposals.